MVA-EbolaZ

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), University of Maryland, Baltimore

Conditions

Ebola Virus DiseaseHemorrhagic FeverHemorrhagic Fever, Ebola

Phase 1

Clinical Trial of Ebola Vaccines cAd3-EBO, cAd3-EBOZ and MVA-EbolaZ in Healthy Adults in Uganda

CompletedNCT02354404

National Institute of Allergy and Infectious Diseases (NIAID)Hemorrhagic Fever, Ebola

Start: 2015-01-27End: 2017-04-19Updated: 2017-12-05

Ebola CVD-Mali #2000 (Bivalent) VRC-EBOAdc069-00-vp (cAd3-EBO)

CompletedNCT02368119

University of Maryland, BaltimoreEbola Virus Disease, Hemorrhagic Fever

Start: 2015-03-31End: 2016-09-27Updated: 2019-09-26

Related Papers

Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials.

2024-03-2910 citations